Novavax Inc (NASDAQ:NVAX) is reportedly expecting to submit its COVID-19 vaccine candidate before US authorities in December.
Chief executive Stanley Erck told Czech paper Hospodarske Noviny that it plans to produce some of the jabs in its Czech plant, so the country will be able to access it if it is approved.
On Monday the biotech enrolled the first volunteer for the Phase II of clinical trials in late August, expanding on Phase I by including older adults 60-84 years of age.
Data is expected in the fourth quarter of 2020.
Shares added 3% to US$118.30 in premarket trading.